A systematic review on the prevalence, pathophysiology, diagnosis, management and treatment of gout (2007-2018)
DOI:
https://doi.org/10.30574/gscbps.2018.5.1.0077Keywords:
Gout, Inflammation, Arthritis, Urate crystals, HyperuricemiaAbstract
Gout is a type of inflammatory arthritis with drastically increasing incidence since last twenty years. Increased serum uric acid levels and deposition of urate crystals in joints and soft tissues are known to stir-up the symptoms of gout. Patient’s quality of life (Qol) suffers markedly due to inflammation, pain, restricted mobility, health economic burden and suboptimal therapeutics associated with gout. Related articles published between 2007 and 2018 were reviewed with the help of different databases including PubMed, Springer link, Medline, Google scholar and Science direct. To ensure the accuracy and credibility of data, articles published only in indexed journals were considered. Gout is a common metabolic disorder that is provoked by increased level of serum uric acid. Presence of other comorbidities i.e. hypertension, diabetes and cardiac diseases precipitate the rate of mortality. Number of gout patients is shown to increase in developed countries whereas developing countries remain at high risk category. The enormous increase in gout is due to chronicity, lack of awareness among patients, poor diagnosis, suboptimal treatment and economic burden. Risk factors associated with gout are well identified and pathophysiology is well-established hence, measures can be taken to improve diagnosis and to ensure cost effective options for the treatment. To curtail the global health burden and to improve patient quality of life there is need: to reduce exposure to risk factors, to promote awareness, to institute robust prophylactic measures, to modify lifestyle, to establish signs for early diagnosis and to develop optimized treatment strategies and policies.
Metrics
References
R Buckley H. (2011). Epidemiology of gout: perspectives from the past.Current Rheumatology Reviews, 7 (2), 106-113.
Doherty M, Jansen TL, Nuki G, Pascual E, Perez-Ruiz F, Punzi L, So AK and Bardin T. (2012). Gout: why is this curable disease so seldom cured? Annals of the rheumatic diseases, annrheumdis-2012-201687.
Hasturk AE, Basmaci M, Canbay S, Vural C and Erten F. (2012). Spinal gout tophus: a very rare cause of radiculopathy. European Spine Journal, 21 (4), 400-403.
Choi HK, Willett W and Curhan G. (2010). Fructose-rich beverages and risk of gout in women. Jama, 304 (20), 2270-2278.
Abeles AM, Park JY, Pillinger MH and Cronstein BN. (2007). Update on gout: Pathophysiology and potential treatments. Current pain and headache reports, 11 (6), 440-446.
Keenan RT, O'Brien WR, Lee KH, Crittenden DB, Fisher MC, Goldfarb DS, Krasnokutsky S, Oh C and Pillinger MH. (2011). Prevalence of contraindications and prescription of pharmacologic therapies for gout. The American journal of medicine, 124 (2), 155-163.
Choi HK and Curhan G. (2007). Independent impact of gout on mortality and risk for coronary heart disease. Circulation, 116 (8), 894-900.
Terkeltaub R. (2010). Update on gout: new therapeutic strategies and options. Nature Reviews Rheumatology, 6 (1), 30-38.
Edwards NL. (2008). The role of hyperuricemia and gout in kidney and cardiovascular disease. Cleveland Clinic journal of medicine, 75 S13-6.
Chilappa CS, Aronow WS, Shapiro D, Sperber K, Patel U and Ash JY. (2010). Gout and hyperuricemia. Comprehensive therapy, 36 3-13.
Seminog OO and Goldacre MJ. (2013). Gout as a risk factor for myocardial infarction and stroke in England: evidence from record linkage studies. Rheumatology, 52 (12), 2251-2259.
Perez‐Ruiz F and Lioté F. (2007). Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout? Arthritis Care & Research, 57 (7), 1324-1328.
Zhou L, Liu L, Liu X, Chen P, Zhang Y, Wu Y, Pettigrew JC, Cheng D and Yi D. (2014). Systematic review and meta-analysis of the clinical efficacy and adverse effects of Chinese herbal decoction for the treatment of gout. PLoS One, 9 (1), e85008.
Smith E, Hoy D, Cross M, Merriman TR, Vos T, Buchbinder R, Woolf A and March L. (2014). The global burden of gout: estimates from the Global Burden of Disease 2010 study. Annals of the rheumatic diseases, 73 (8), 1470-1476.
Dalbeth N, Petrie KJ, House M, Chong J, Leung W, Chegudi R, Horne A, Gamble G, McQueen FM and Taylor WJ. (2011). Illness perceptions in patients with gout and the relationship with progression of musculoskeletal disability. Arthritis Care & Research, 63 (11), 1605-1612.
Spencer K, Carr A and Doherty M. (2012). Patient and provider barriers to effective management of gout in general practice: a qualitative study. Annals of the rheumatic diseases, 71 (9), 1490-1495.
Kiadaliri AA and Englund M. (2018). Temporal trends and regional disparity in rheumatoid arthritis and gout hospitalizations in Sweden, 1998–2015. Clinical Rheumatology, 1-6.
Wertheimer A, Morlock R and Becker MA. (2013). A revised estimate of the burden of illness of gout. Current Therapeutic Research, 75 1-4.
Simeunovic Ostojic M and Maas J. (2018). Anorexia nervosa and uric acid beyond gout: An idea worth researching. International Journal of Eating Disorders,
Dehghan A, Köttgen A, Yang Q, Hwang S-J, Kao WL, Rivadeneira F, Boerwinkle E, Levy D, Hofman A and Astor BC. (2008). Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. The Lancet, 372 (9654), 1953-1961.
Roddy E and Doherty M. (2010).Gout. Epidemiology of gout.Arthritis research & therapy, 12 (6), 223.
Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, Gabriel S, Hirsch R, Hochberg MC and Hunder GG. (2008). Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part II. Arthritis & Rheumatology, 58 (1), 26-35.
Kuo C-F, Grainge MJ, Mallen C, Zhang W and Doherty M. (2014). Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Annals of the rheumatic diseases, annrheumdis-2013-204463.
Hollis‐Moffatt JE, Xu X, Dalbeth N, Merriman ME, Topless R, Waddell C, Gow PJ, Harrison AA, Highton J and Jones PB. (2009). Role of the urate transporter SLC2A9 gene in susceptibility to gout in New Zealand Māori, Pacific Island, and Caucasian case–control sample sets. Arthritis & Rheumatology, 60 (11), 3485-3492.
Krishnan E, Lienesch D and Kwoh CK. (2008). Gout in ambulatory care settings in the United States. The Journal of rheumatology, 35 (3), 498-501.
Liu R, Han C, Wu D, Xia X, Gu J, Guan H, Shan Z and Teng W. (2015). Prevalence of hyperuricemia and gout in mainland China from 2000 to 2014: A systematic review and meta-analysis. BioMed research international, 2015
Khanna PP, Nuki G, Bardin T, Tausche A-K, Forsythe A, Goren A, Vietri J and Khanna D. (2012). Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: results from a cross-sectional survey. Health and quality of life outcomes, 10 (1), 117.
So AK and Martinon F. (2017). Inflammation in gout: mechanisms and therapeutic targets. Nature Reviews Rheumatology, 13 (11), 639.
Maiuolo J, Oppedisano F, Gratteri S, Muscoli C and Mollace V. (2016). Regulation of uric acid metabolism and excretion. International journal of cardiology, 213 8-14.
Taniguchi A and Kamatani N. (2008). Control of renal uric acid excretion and gout. Current opinion in rheumatology, 20 (2), 192-197.
Eraly SA, Vallon V, Rieg T, Gangoiti JA, Wikoff WR, Siuzdak G, Barshop BA and Nigam SK. (2008). Multiple organic anion transporters contribute to net renal excretion of uric acid. Physiological genomics, 33 (2), 180-192.
Schett G, Schauer C, Hoffmann M and Herrmann M. (2015). Why does the gout attack stop? A roadmap for the immune pathogenesis of gout. RMD open, 1 (Suppl 1), e000046.
So A. (2007). Recent advances in the pathophysiology of hyperuricemia and gout. Revue medicale suisse, 3 (103), 720, 722-4.
Seth R, Kydd A, Buchbinder R, Bombardier C and Edwards CJ. (2013). Allopurinol for chronic gout. Cochrane Database Syst Rev, 4
Eggebeen AT. (2007). Gout: an update. American family physician, 76 (6),
Busso N and So A. (2010).Gout. Mechanisms of inflammation in gout.Arthritis research & therapy, 12 (2), 206.
Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, Pillinger MH, Merill J, Lee S and Prakash S. (2012). 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care & Research, 64 (10), 1431-1446.
Doghramji PP and Wortmann RL. (2012). Hyperuricemia and gout: new concepts in diagnosis and management. Postgraduate medicine, 124 (6), 98-109.
Mandell BF. (2008). Clinical manifestations of hyperuricemia and gout. Cleveland Clinic journal of medicine, 75 S5-8.
Dalbeth N, Aati O, Gao A, House M, Liu Q, Horne A, Doyle A and McQueen FM. (2012). Assessment of tophus size: a comparison between physical measurement methods and dual-energy computed tomography scanning. JCR: Journal of Clinical Rheumatology, 18 (1), 23-27.
Edwards N, Sundy J, Forsythe A, Blume S, Pan F and Becker M. (2011). Work productivity loss due to flares in patients with chronic gout refractory to conventional therapy. Journal of medical economics, 14 (1), 10-15.
Yazdanyar A, Rizzuti AE, Mechel E, Denisova K and Lazzaro DR. (2018). Gout keratitis: a case of peripheral ulcerative keratitis secondary to gout with a review of the literature. Cornea, 37 (3), 379-381.
Peláez-Ballestas I, Cuevas CH, Burgos-Vargas R, Roque LH, Terán L, Espinoza J, Esquivel-Valerio JA, Goycochea-Robles MV, Aceves FJ and Bernard AG. (2010). Diagnosis of chronic gout: evaluating the american college of rheumatology proposal, European league against rheumatism recommendations, and clinical judgment. The Journal of rheumatology, 37 (8), 1743-1748.
Dore RK. (2008). The gout diagnosis. Cleveland Clinic journal of medicine, 75 S17-21.
Glazebrook KN, Guimarães LS, Murthy NS, Black DF, Bongartz T, J. Manek N, Leng S, Fletcher JG and McCollough CH. (2011). Identification of intraarticular and periarticular uric acid crystals with dual-energy CT: initial evaluation. Radiology, 261 (2), 516-524.
Choi HK, Al-Arfaj AM, Eftekhari A, Munk PL, Shojania K, Reid G and Nicolaou S. (2009). Dual energy computed tomography in tophaceous gout. Annals of the rheumatic diseases, 68 (10), 1609-1612.
Perez-Ruiz F, Dalbeth N and Bardin T. (2015). A review of uric acid, crystal deposition disease, and gout. Advances in therapy, 32 (1), 31-41.
Choi HK and Curhan G. (2008). Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. Bmj, 336 (7639), 309-312.
Hak AE and Choi HK. (2008). Lifestyle and gout. Current opinion in rheumatology, 20 (2), 179-186.
Liebman SE, Taylor JG and Bushinsky DA. (2007). Uric acid nephrolithiasis. Current rheumatology reports, 9 (3), 251-257.
Choi HK. (2010). A prescription for lifestyle change in patients with hyperuricemia and gout. Current opinion in rheumatology, 22 (2), 165-172.
Sundy JS and Hershfield MS. (2007). Uricase and other novel agents for the management of patients with treatment-failure gout. Current rheumatology reports, 9 (3), 258-264.
Sivera F, Wechalekar MD, Andrés M, Buchbinder R and Carmona L. (2012). Interleukin-1 inhibitors for acute gout. The Cochrane database of systematic reviews, 9
Diaz-Torné C, Perez-Herrero N and Perez-Ruiz F. (2015). New medications in development for the treatment of hyperuricemia of gout. Current opinion in rheumatology, 27 (2), 164-169.
Janssens HJ, Lucassen PL, Van de Laar FA, Janssen M and Van de Lisdonk EH. (2008). Systemic corticosteroids for acute gout. The Cochrane Library,
Stevenson M and Pandor A. (2011). Febuxostat for the management of hyperuricaemia in patients with gout. Pharmacoeconomics, 29 (2), 133-140.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
